This work provides insights into the role CD99 plays in the CNS leukemia niche and supports directly targeting CD99, or modulating its downstream pathways, as potential approaches for overcoming meningeal-mediated leukemia chemoresistance. The gene discussed is CD99; the disease is leukemia.